Delving into the Latest Updates on Noorda College of Osteopathic Medicine LLC with Synapse

Overview

Tags

Other Diseases

Endocrinology and Metabolic Disease

Nervous System Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Disease Domain	Count

Nervous System Diseases	3
Neoplasms	3
Endocrinology and Metabolic Disease	3
Infectious Diseases	1
Immune System Diseases	1
Hemic and Lymphatic Diseases	1

Top 5 Drug Type	Count

Small molecule drug	3

Open fracture-related infection challenges persist in healthcare. From the time open fractures were defined ∼50 years ago, infection rates have gone essentially unchanged. Contributing factors include compromised vasculature, biofilm, and stalled innovations in treatment and prophylaxis. In this study, we engineered and tested the efficacy of a refillable drug delivery device, the Purgo Pouch (Pouch), that sustains local, high dose intrawound antibiotic concentrations in wound sites. We hypothesized that it would manage biofilm-compromised open fracture-related infection better than clinical standards of care. Therapies were tested in a unique sheep model of long bone open fracture-related infection with compromised tissue and biofilm inocula of methicillin-resistant Staphylococcus aureus. Sheep (n = 5/group) were treated with IV vancomycin (10 days), gentamicin-loaded CaSO₄ beads (single application), or the Pouch (10 days) loaded with gentamicin alone or a triple antibiotic combination. At 21 days, sheep were euthanized and microbiological and histological data collected. Results indicated that the Pouch managed infection more effectively, reducing bioburden to <10⁵ colony forming units (CFU)/sample, which was statistically significant compared to clinical standards, which failed to reduce bioburden to below 10⁵ CFU. The hypothesis was supported. The Pouch received Breakthrough Device Designation by the FDA, is being transitioned toward clinical trials, and is a potential solution to the long-standing problem of open fracture-related infection.

01 Jun 2025·American Journal of Ophthalmology Case Reports

Intracorneal epithelial ingrowth following sutureless clear corneal cataract surgery

Article

Author: Turner, Elizabeth L ; Helm, Craig J

PurposeTo report an unusual case and long-term follow-up of isolated intracorneal epithelial ingrowth following sutureless, clear corneal cataract surgery.MethodsA 77-year-old patient was first noted to have a deep corneal opacity in an eye 19 months following uncomplicated sutureless clear corneal cataract surgery. From then on, the lesion was seen to become denser and the patient was referred for corneal consultation. Uncorrected visual acuity in the eye measured 20/25. Slit lamp examination found a 1.4 × 1.7 mm whitish lesion located in the pre-Descemet's space. The lesion began at the anterior edge of the cataract incision and extended centrally. The lesion was observed over a 10-year period.ResultsAfter first noticing the opacity 19 months after cataract surgery, it took an additional 16 months for the lesion to start to regress clinically. At no time was the visual acuity adversely affected. Ultimately, the lesion resolved to a mild deep scar over a 10-year observation period.ConclusionsAn isolated peripheral island of epithelium in the Pre-Descemet's space can be safely observed without intervention as long as it does not affect visual acuity.

01 May 2025·JAAD Case Reports

Treatment of recalcitrant hypertrophic lichen planus with upadacitinib

Article

Author: Noot, Christiaan H ; Hopkins, Zachary H ; Schundler, Sabrina F ; Frost, Zachary ; Clarke, Jennie

100 Deals associated with Noorda College of Osteopathic Medicine LLC

Login to view more data

100 Translational Medicine associated with Noorda College of Osteopathic Medicine LLC

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 10 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

3

Login to view more data